New insider activity at Cytokinetics ( (CYTK) ) has taken place on October 7, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EVP of Research & Development, Fady Ibraham Malik, has recently sold 2,000 shares of Cytokinetics stock, amounting to a total transaction value of $121,120.
Recent Updates on CYTK stock
Cytokinetics has seen significant developments over the past 24 hours, primarily driven by positive data and analyst updates regarding its drug aficamten. Barclays raised its price target for Cytokinetics, citing a high probability of success in the aficamten Phase 3 ACACIA trial for nonobstructive hypertrophic cardiomyopathy, which could make it the first approved treatment in this area. BofA also increased its price target, acknowledging the competitive data for aficamten but expressing some reservations about execution. B. Riley raised its price target as well, following positive feedback from a late-cycle FDA meeting about aficamten, which supports a differentiated Risk Evaluation and Mitigation Strategies (REMS) program. Additionally, Cytokinetics presented promising trial results at the Heart Failure Society of America meeting, showing aficamten’s superior efficacy over metoprolol in exercise performance and long-term safety in non-obstructive hypertrophic cardiomyopathy. These developments have bolstered the stock’s outlook as the company anticipates FDA approval by the end of the year.
Spark’s Take on CYTK Stock
According to Spark, TipRanks’ AI Analyst, CYTK is a Neutral.
Cytokinetics’ overall stock score is primarily impacted by its financial instability and ongoing losses, which are significant risks. However, strong technical indicators and positive corporate events provide some optimism. The company’s future prospects hinge on successful regulatory approvals and commercialization of aficamten.
To see Spark’s full report on CYTK stock, click here.
More about Cytokinetics
YTD Price Performance: 23.93%
Average Trading Volume: 2,159,586
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.26B